ENDO

Once-daily fezolinetant tied to significant reduction in VMS frequency, severity

Data on long-term safety needed, however

5-year survival rates were not affected, however

Findings reinforce importance of early screening and intervention, researchers says

Other noteworthy research presented at the Endocrine Society's annual meeting

Pooled trial data show no link to breast cancer

Association could be attributed to gender-affirming hormone therapy, researcher says

Continued weight loss beyond 1 year while on drug; patients switched to placebo gained it back

Study looked at hospitalized patient outcomes during early months of the pandemic

Very -- in fact, "quite alarming," researcher says

Real-world data offer word of caution for oncologists

Outpatient duodenal mucosal resurfacing procedure showed broad range of metabolic benefits

Numerically small but statistically and clinically significant benefit

Other noteworthy research presented at The Endocrine Society annual meeting